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(SPARAO)

is

characterized by reversible airway obstruction resulting from airway hyper-reactivity to
aeroallergens, mucus accumulation, and airway inflammation. These are key clinical
features that are shared with human asthma, suggesting SPARAO’s utility as an animal
asthma model.
SPARAO affects horses maintained on pasture in conditions of high heat and
humidity. Common in the southeastern United States, the cause of SPARAO is unknown,
but is presumed to reflect reactivity to seasonally inhaled pasture-associated
aeroallergens.
This investigation sought to identify well-characterized histopathological lesions
of human asthma, collectively termed ‘asthmatic remodeling’, in lung tissue from horses
with SPARAO. Two histological staining techniques were used: H&E and Movat’s
Pentachrome. Similar to chronic asthma, lung tissue from horses with SPARAO
demonstrates statistically significant increases in airway smooth muscle, fibrosis, airway
occlusion and inflammation, goblet cell hyperplasia, and remodeling of terminal
bronchioles and elastin fibers.
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CHAPTER I
INTRODUCTION

Recurrent airway obstruction (RAO), an asthma-like disease, is one of the most
frequent respiratory diseases in horses,1 and is generally recognized as a disease that
occurs in mature horses worldwide that are housed in stalls.2-4 RAO is a naturally
occurring allergic respiratory disorder characterized by exacerbations of acute airway
obstruction followed by periods of remission.5 Airway obstruction results from
bronchospasm, mucus accumulation, and airway inflammation.6 Risk factors associated
with disease onset reflect increased aeroallergen/organic particle exposure and include
inadequate air circulation, direct exposure to environmental aero-allergens (especially
mold spores and pollen), exposure to stalls or barns with poor air quality, and the use of
poor quality dusty or moldy hay.7 Conversely, disease remission is associated with
allergen depletion in the environment of RAO affected horses.8
RAO is an economically significant disease of horses for which two syndromes
have been described. Barn-associated RAO occurs more commonly in temperate
climates,8 and summer pasture-associated recurrent airway obstruction (SPARAO) which
affects horses maintained in pasture during summer in the southeastern United States and
Great Britain.4,9 The incidence of RAO is rare in warm and dry climates such as in
California and Australia.8 Barn-associated RAO is typically a disease of stabled horses
during the winter.1,10 Though the stimuli eliciting barn-associated RAO are likely
1

complex and diverse, the disease is reliably triggered by challenge with organic molds
that are found in hay.10 Clinical signs can be improved by reducing or eliminating dust
and increasing ventilation in the stall.7, 10 Eliminating allergens that precipitate the
clinical syndrome is essential to prevent and manage the disease.3
Unlike barn-associated RAO, SPARAO is reported in mature horses housed
primarily on pasture during the spring and summer.11 SPARAO affected horses
experience a seasonal remission of clinical signs during the winter.11 Inhalation of pollens
and/or outdoor molds are thought to be the main cause of this summer condition.12
However, clinical exacerbation of SPARAO is associated with increases in temperature,
humidity, counts of fungal spores and counts of grass pollens.13
Pulmonary obstruction can involve central and/or terminal airways.14 While
terminal airways provide little resistance to airflow in normal lung, investigations in
human asthmatics suggest that small airways are responsible for the majority of gas
trapping in the asthmatic lung.15 Though histopathologic lesions in large airways of
human asthmatics are well characterized because they are easily accessible for
endoscopic biopsy, histopathology of the terminal airways in human asthma is not well
characterized.
Significantly, RAO possesses key clinical features of asthma16 including
reversible airway obstruction, bronchial hyper-reactivity to aeroallergens, and chronic
airway inflammation.2,6,7,13 The objective of this research is to identify histopathologic
lesions that are common to the small airways of SPARAO affected horses and the small
airways of human asthmatics.

2
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CHAPTER II
LITERATURE REVIEW

Recurrent Airway Obstruction and Summer Pasture-Associated Recurrent
Airway Obstruction
Recurrent Airway Obstruction (RAO, “heaves”) is a frequent equine pulmonary
disease in the northern hemisphere.1 It is an asthma-like condition of stabled horses
characterized by reversible airway obstruction and airway inflammation that is initiated
by inhalation of organic particles, especially from hay and bedding.2 Horses with summer
pasture-associated recurrent airway obstruction (SPARAO) also exhibit these asthma-like
signs resulting in a syndrome that is clinically similar to barn-associated RAO. However,
SPARAO occurs from spring until early fall in horses that are exposed to pasture in warm
climates.3 Horses can, infrequently, be affected by both forms of the disease.4 Both
recurrent airway obstruction and summer pasture-associated recurrent airway obstruction
(RAO-SPARAO) are characterized by reversible airflow obstruction, airway neutrophilic
inflammation, and mucus hypersecretion.3,5 Bronchial hyper-responsiveness is well
documented in RAO4 and while presumed to occur in SPARAO, has not been
experimentally documented.3 RAO and SPARAO occur as a clinical syndrome ranging
from exercise intolerance and coughing to tachypnea, dyspnea, and wheezing. In both
RAO and SPARAO, remission is observed when the allergen is removed from the horse
environment.3,6 RAO and SPARAO have been previously referred to as chronic
5

obstructive pulmonary disease (COPD). However, in human COPD, airway obstruction is
minimally reversible and airway hyper-reactivity is not a predominant facet of the
disease. These and other differences make RAO and SPARAO more analogous to human
asthma.2
Both RAO and SPARAO are considered to be caused by mixed hypersensitivity
reactions to aeroallergens, especially molds and endotoxins. The precise
immunopathological mechanisms and antigens responsible for causing the clinical
syndrome in susceptible animals have not been fully elucidated.1, 7 Intradermal tests have
confirmed hypersensitivity to numerous antigens, but the development of skin
hypersensitivity does not assure a causative relationship for RAO.8 Allergens triggering
SPARAO appear to be related to pasture, particularly pollen and outdoor molds3, 9 as
evidenced by clinical worsening when exposed to pasture and improvement when horses
with SPARAO are removed from pasture. It was reported that mature horses that are kept
in pasture for more than 12 hours a day are more susceptible to develop SPARAO.10, 11
Both RAO and SPARAO are multifactorial diseases that result from genetic and
environmental interactions. A poorly ventilated stall may trigger RAO, but a poorly
ventilated stall in association with a genetically predisposed horse make the disease more
severe.12 Marti and collaborators (1991) demonstrated that offspring from horses with
allergic pulmonary disease have an increased risk of developing chronic pulmonary
hypersensitivity and this risk increases when both the sire and dam are affected by an
allergic pulmonary disease.13
Although RAO is the most common chronic respiratory condition in stabled
mature horses in the northern hemisphere,14 its occurrence is rare in warm and dry
6

climates such as California and Australia.6 Conversely, SPARAO has been reported in
regions with warm and humid summers such as the southeastern United States and the
United Kingdom.9,10,15 An epidemiologic study from 1998 that included 28 states from
the United States demonstrated that 43% of winter stabled horses are RAO-affected.15 In
addition, a study of risk factors for RAO in North American horses identified a
considerably increased risk of RAO with increasing age. Horses greater than or equal to 7
years of age are 6 to 7 times more likely to develop RAO than younger horses.16 In 2007,
a study of RAO prevalence in Great Britain demonstrated that 14% of the horses were
RAO-affected. That same study concluded that increasing age and exposure to an
urbanized environment are risk factors for RAO and suggested that air pollution was
responsible for RAO in urban areas.17 A 2011 prevalence study also identified RAO as
the most diagnosed veterinary pulmonary disease in Hungary.18 RAO is also more
prevalent than SPARAO in Britain where maintaining horses on pastures as long as
possible is recommended.19
Clinical signs of RAO result from airflow obstruction which occurs secondary to
diffuse bronchoconstriction.14 The most common signs are flared nostrils, increased
respiratory rate, anxiety, coughing, nasal discharge and reduced exercise tolerance. In the
most severe cases a heave line, reflecting hypertrophy of the external abdominal oblique
muscle, is evident.20 In RAO, clinical signs are more expected during the winter while
SPARAO clinical signs become more accentuated from July to September with a period
of remission during the winter.11
The pathogenesis of RAO and SPARAO have been gradually clarified by the
continual application of new research tools. RAO has been investigated to a much greater
7

extent than SPARAO. Both innate and adaptive immunity contribute to the inflammatory
process that is characteristic of RAO.21 Van der Haegen, et. al., (2005) demonstrated that
IgE-positive cells (IgE+) are present in lung tissue of RAO-affected horses but the
numbers of IgE positive cells did not differ between affected and control horses.24
However, Dirscherl demonstrated that relative to basophils from control horses without
RAO, basophils from horses with barn RAO were hypersensitized to a number of
antigens, particularly molds of the genus Mucor. This work substantiates, in at least some
cases of RAO, a role for IgE sensitized inflammatory cells as the gateway to antigenspecific recognition and initiation of inflammatory cascades.22
Following allergen exposure, susceptible horses develop airway inflammation
characterized by a massive neutrophil influx.23 Transcription factor activation,
particularly of NF-κB, plays an important role in regulating cellular pathways responsible
for the clinical syndrome.24 Inflammatory cell activation by helper T-cells has been
identified in RAO and the intensity of cytokine production has been correlated to disease
chronicity.23 Bronchoalveolar cells from RAO-affected horses have an increased
expression of IL-4 and IL-5 mRNA, and decreased expression of INF-γ consistent with
the Th-2 cytokine profile that has been often demonstrated in human asthma.25
Tamarinde, et. al., (2006) further corroborated a Th2 polarization in RAO, demonstrating
increased expression of TNF-α, IL-1β and IL-8 in alveolar macrophages from RAOsusceptible horses relative to horses without RAO following sensitization. Expression of
the anti-inflammatory cytokine, IL-6 was higher in the RAO susceptible groups after 6
hours of allergen challenge relative to horses that were not susceptible to RAO.21
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Specific mediators of disease include, but are not limited to chymase, mucin and
endothelin-1. Van der Haegen, et. al., (2005) demonstrated a relationship between high
chymase+ mast cell (MCc) numbers in the bronchial wall and lung fibrosis, suggesting
that MCc may be involved in the tissue remodeling associated with RAO.26 Lugo, et. al.,
(2006) showed that the amount of stored mucin in goblet cells increases with airway
inflammation in RAO.27 Endothelin-1 (ET-1) is a powerful smooth muscle constriction
and proinflammatory mediator that has been implicated in the pathogenesis of asthma.
Benamou (1998) showed that the production and release of ET-1 is increased during a
RAO exacerbation.28 Costa corroborated this finding in SPARAO, demonstrating a
significantly higher ET-1 concentration in plasma, BALF and pulmonary epithelial lining
fluid from SPARAO affected horses during seasonal clinical exacerbation relative to their
ET-1 concentrations in the season of disease remission (and relative to ET-1
concentrations of control horses during the period of clinical exacerbation). A 2008 study
also revealed ET receptor expression to be higher in the peripheral lungs of SPARAOaffected horses relative to controls.29 Cytological analysis of bronchoalveolar lavage fluid
(BALF) is commonly employed to diagnose RAO and SPARAO. This method is simple,
inexpensive and can be used for differentiating pulmonary infections and pulmonary
inflammation.30 Kutasi and collaborators (2001) concluded that historic analysis and
clinical examination are not sufficient to diagnose RAO and SPARAO, yet veterinarians
infrequently use auxiliary tests to confirm the disease. Also they demonstrated that the
age of the horse, history, clinical examination, respiratory tract endoscopy and BALF are
the most valuable test combination to diagnose pulmonary allergic diseases in horses.18
While measures of lung function including resistance and elastance are evaluated in
9

airway research involving RAO and SPARAO, the equipment necessary to evaluate lung
function is not well suited to its use in field practice.14
Though RAO and SPARAO are chronic and progressive, medical therapy and
environmental management can be effective in controlling the disease.31 However,
because RAO and SPARAO are allergic diseases, eliminating the inciting antigens is
crucial for effective response to therapy.11 For both RAO and SPARAO, prognosis
depends upon disease severity at the time of diagnosis and vigilant environmental
management. Controlling airway inflammation and airway hyper-reactivity are important
therapeutic goals.20
Pulmonary Histopathologic Alterations in RAO-SPARAO
RAO and SPARAO share similar histologic lesions32. However, RAO has been
studied with more frequency than SPARAO due its higher incidence and earlier
discovery.
Mucus hypersecretion is an important feature of RAO and SPARAO which is
present even during clinical remission of the disease.33, 34 Mucus accumulation in the
airways contributes to exacerbation of clinical signs.35 Costa, et. al., (2000), described
mucus accumulation as the main change in small airways of SPARAO-affected horses32
and Polikepahad, et. al., (2008)30 also suggested that the most prevalent histopathologic
change in euthanized SPARAO-affected horses is mucus accumulation.
The inflammatory process in RAO and SPARAO is characterized by a
predominance of neutrophilic infiltration which can vary in severity.10,26 A minor and
occasional eosinophilic infiltration may also be present.33 Lugo, et. al., (2006)
demonstrated that in RAO-affected horses, this pulmonary inflammatory infiltrate is
10

located mainly in the peribronchiolar interstitial tissue, lamina propria and luminal
surface of the airways.27
Herszberg, et. al., (2006) used histomorphometry to demonstrate that RAO is
characterized by an important increase of airway smooth muscle in small and large
airways. Moreover, the same study demonstrated that this smooth muscle increase is
associated with myocyte hyperplasia.36 Mujahid, et. al., (2011) also used
histomorphometry to show that increasing airway smooth muscle is a feature of
SPARAO.37 Additional research is warranted to clarify the degree to which airway
smooth muscle proliferation contributes to airway remodeling and how this process
occurs in RAO.
Airways of RAO affected horses exhibit goblet cell hyperplasia.35 Furness, et. al.,
(2010) demonstrated the presence of goblet cells in noncartilaginous airways of RAOaffected horses, a histopathologic change correctly termed metaplasia and not
hyperplasia, as they assumed.38 Costa (2000) followed by Polikepahad (2008) also
confirmed the presence of goblet cell metaplasia in noncartilaginous airways of
SPARAO-affected horses.29,33
Fibrosis was not considered an important histologic change in RAO-affected
horses by Furness and collaborators (2010). They used an immunohistochemistry method
to measure the distribution of collagen in noncartilaginous airways. As a result, they did
not detect considerable collagen proliferation in RAO-affected horses.38 Likewise, Costa,
et. al., (2000) did not observe appreciable collagen or fibrosis in SPARAO lung.32
Though the pulmonary histopathologic alterations in RAO and SPARAO are quite
similar, equine allergic pulmonary disease is very complex. Therefore, more studies are
11

necessary to confirm the histopathologic findings in both conditions. Changes evident in
asthma including elastic fiber proliferation and neovascularization have not been studied
in RAO or SPARAO-affected horses, to date. In addition, some researchers have
confused pathologic terminology, especially metaplasia, that has been frequently referred
to as hyperplasia.
Histopathology of Asthmatic lungs
Macroscopic examination of a human asthmatic lung shows hemorrhagic changes,
edema and hyperinflation of small airways.39 Asthmatic lung presents various
histopathologic alterations that are observed in cartilaginous (proximal) and
noncartilaginous (distal) airways.39 Tissue remodeling in the airways correlates to asthma
severity.40 In the human respiratory tract, air is distributed into more than 130,000
terminal airways (<2mm) and each terminal airway is subdivided into alveolar ducts and
alveoli.41 Although noncartilaginous airways contribute to only a small proportion of
airway resistance, pulmonary physiology is highly influenced by histologic alterations in
noncartilaginous airways.42 Accordingly, in an asthmatic exacerbation, small airways
may have an important influence on lung physiology.43 Studies involving
noncartilaginous airways have been limited because their small caliber makes these
airways difficult to access. Nonetheless, transbronchial biopsy, morphometry,
biochemical markers, flow-volume analysis and high-resolution imaging have been used
to explore the peripheral lung and to improve the understanding of noncartilaginous
airways in asthma.44, 45 Since residual volume of air caused by closure of terminal
airways increases with age, Macklem46 has suggested that terminal bronchioles are
responsible for the majority of gas trapping in asthma.
12

Components of the chronic inflammatory process are suggested to be the main
cause of architectural remodeling, irreversible airway obstruction and asthma severity47,
48

. Eosinophils are the main inflammatory cell in asthmatic lung and variation in the

distribution of this inflammatory cell type has been noticed. Small airways show more
eosinophilic accumulation within the airway wall whereas the density of eosinophils
within the lumen is greater in the lumen of the large airways.49 Consistent inflammation,
especially eosinophilic, has an important role in determining asthma severity.50, 51
Lacoste, et. al., demonstrated an increased number of eosinophils in the blood, BALF and
pulmonary biopsy of asthmatic patients. In addition, they also confirmed the presence of
degranulated eosinophils only in asthmatic patients, when compared to COPD-affected
and normal subjects.52 Carroll and collaborators (1996) demonstrated that the number of
neutrophils increases and the number of eosinophils decreases in fatal asthma attacks of
short duration, when compared to fatal asthma attacks of long duration. These findings
have led to the proposal that asthma attacks are triggered by an inflammatory stimulus.53
Ordonez and colleagues (2000) also concluded that neutrophils are the most common
inflammatory cell in the airways in acute severe asthma.54
Airway smooth muscle proliferation is one of the most important alterations in
asthmatic lungs. It is associated with asthma severity48, 55 and it increases with age.56
Prescott and collaborators (2004) demonstrated that airway smooth muscle proliferation
is a feature of mild to moderate asthma. Further, they concluded that this proliferation is
attributable to smooth muscle hyperplasia and that smooth muscle hypertrophy does not
occur.57
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Goblet cell hyperplasia is an important characteristic of asthma. Ordonez, et. al.,
(2001) demonstrated that in mild asthma the hyperplastic goblet cells increase mucin
storage while in moderate asthma the mucin is overstored and secreted. The same study
suggested that goblet cell hypertrophy does not occur and secretion of mucin may be
related to asthma severity.58 Additionally, Aikawa and colleagues (1992) revealed that
goblet cell hyperplasia is a prominent characteristic of patients who died from an asthma
attack.59
Histopathologic alteration in the airway epithelial tissue has been considered the
major feature of airway remodeling in asthmatic lungs and the airway inflammatory
process is also influenced by epithelial cells.60 Loss of integrity, cellular detachment and
squamous cell metaplasia are routinely observed, especially in the most severe cases.61
Subepithelial collagen deposition is a primary histopathologic alteration observed
in asthmatic lungs.62 Chu, et. al., (1998) demonstrated that collagen deposition in large
airways is a feature of asthma, but that it does not correlate to disease severity.47
Opposing these results, Benayoun, et. al., (2003), demonstrated that collagen deposition
and fibroblast accumulation in large airways are determinates of asthma severity.55
Elastic fiber proliferation is a feature of asthmatic lungs that has not been
correlated to disease severity. Carrol, et. al., (2000) performed a histopathologic study of
small and large asthmatic airways and demonstrated that elastic fiber proliferation in fatal
asthma is similar to nonfatal cases, whereas nonasthmatic control cases showed a
decrease in the quantity of elastic fibers.63
In summary, asthma is a heterogeneous condition. Some pulmonary
histopathologic alterations correlate to asthma severity. Though inflammatory cell
14

composition has been extensively studied, characteristics including airway smooth
muscle proliferation, collagen deposition and elastic fiber accumulation are in need of
more extensive research.
Animal models of asthma
A variety of animal species have been used as asthma models. However, the
histopathologic and immunologic complexities of asthma make64 it challenging to
identify an animal model capable of mimicking all the characteristics of human asthma.
A perfect animal model for human asthma research should exhibit all the signs presented
in the human disease, including cough, wheeze, bronchoconstriction, airway
inflammation, airway hyperresponsiveness, airway remodeling and decreasing lung
function. Animal models are very important to identify and test the efficacy and safety of
new drugs.65 Only horse and cat develop a spontaneous asthma-like syndrome that
demonstrates a high level of similarity to the human condition.66 Other animal asthma
models have been induced in mouse, guinea pig, dog, sheep, and nonhuman primates.
The characteristics of each animal model influence its suitability for investigating
particular facets of asthma. Accordingly, the success of a given research hypothesis is
largely influenced by the selection and suitability of the animal model that is
investigated.67
Murine model
The murine model is the most common animal asthma model.65, 68 Mice are
inexpensive, breed rapidly, are available in genetically homogenous strains and are easily
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handled. In addition, a great variety of transgenic strains are available for focused
mechanistic research.
Transgenic mice are particularly useful to characterize key events and effector
molecules that regulate airway inflammation.69, 70 However, the efficacy of mice models
in studies of small-molecule therapeutics and their specific receptors is dubious, since the
rodent receptors and signal-transduction pathways diverge significantly from those of
humans.71 A vast number of different murine protocols are used for asthma studies but
ovalbumin (OVA) is the most used antigen to induce asthma and intraperitoneal injection
is the most frequent route of sensitization.72 This method is completely different from the
naturally occurring human disease in which sensitization occurs via the respiratory tract.
In addition, OVA does not trigger asthma in humans and allergens that trigger the human
condition, such as pollen, dust, mites and molds, do not induce asthma in mice.68, 73
Important differences between human asthma and the murine model have limited
use of murine models in asthma research. Research mice are housed in an environment
that is not similar to the human condition, the number of branching airways and
submucosal glands are fewer in mouse lungs than human, and the airways are large
relative to the size of the organism.74 In addition, airway hyperresponsiveness in humans
is immensely greater than in the mouse. Human asthma is also more restricted to the
airways while the murine condition extends to the lung parenchyma and pleura.75 In
contrast to human asthma, the murine model also does not show airway smooth muscle
increase or a late asthmatic response.76-78 Another disadvantage is the fact that prolonged
antigen exposure inhibits eosinophilic inflammation and prevents further exacerbations
trigged by the same antigen. Moreover, airway hyperresponsiveness is also inhibited by
16

prolonged antigen exposure.79, 80 The murine model also fails to simulate chronic
inflammation and epithelial alterations, both important characteristics of human asthma
that are not present in rodents. Also, the inflammatory process and the detected airway
hyperreactivity cease after removing the allergen exposure. These collective limitations
have led to questions regarding the applicability of the mouse model.70, 81
Recently, several alternative murine models have been tested with the goal to
better simulate the histopathological alterations and immunological processes that occur
in human asthma in order to make the mouse more useful in asthma research.70, 82-86
Guinea Pig model
The guinea pig has been recognized as an important model for human asthma
studies. They are small, docile, inexpensive and easily handled. Moreover, this model
presents a histological and clinical asthmatic condition similar to human asthma.87
Guinea pig asthma exhibits airway remodeling, inflammation and hyperresponsiveness.8891

Accordingly, the guinea pig is well suited for airway hyperresponsiveness research and

has been extensively employed in investigations of airway hyperresponsiveness.92
In contrast to mice and rats, the guinea pig is capable of developing early and late
asthmatic responses and during the late response, eosinophilic and neutrophilic
inflammation are observed.91 A recent asthma study with guinea pig models also revealed
that airway eosinophilia and airway hyperresponsiveness may occur in association with
each other, but a causal association between these factors was not demonstrated.93
The use of the guinea pig model in asthma research has important limitations.
This model has a scarceness of genetically modified animals, lack of appropriate speciesspecific reagents such as antibodies and cytokines, and it overreacts to histamine
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challenge when compared to the human reaction.64, 94 Additionally, in contrast to the
spontaneous asthmatic development in humans, the asthmatic condition in guinea pigs
requires induction by antigen sensitization.88, 89, 93-96
Feline Model
Due to the spontaneous development of asthma in cats, the feline model is
considered an interesting and valuable animal model for asthma research.97 A variety of
immunologic, physiologic and pathologic alterations that resemble human asthma are
present in feline asthma.98 Prevalence of feline asthma syndrome is unknown because a
large number of affected cats are not reported by their owners.99 The correct diagnosis of
asthma is made by analysis of clinical signs and radiographic findings, including chronic
cough, examination of bronchial wall thickening by radiography, high eosinophil counts
in cytology of tracheobronchial secretions and history of rapid recovery from tachypnea
after using bronchodilators. These are also characteristics found in eosinophilic human
asthma.100
Especially under chronic exposure to allergen, the feline model is capable of
representing important characteristics of human asthma such as eosinophilic airway
inflammation, airway hyperresponsiveness, airway remodeling, airway smooth muscle
thickening, goblet cell hyperplasia, and allergen-specific IgE.98, 104 In addition, acute
clinical signs of the human condition, such as cough, wheezing and tachypnea, are also
reported.64, 98, 99, 101-103
Disadvantages of using cats as an animal model for human asthma include limited
numbers of interventions that can be tolerated due to their small body size.103 Molecular
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tools are also poorly developed for feline models,104 and ethical issues have decreased
asthma research in the feline model.
Canine Model
The dog has been used for asthma research involving long-term exposure to
inhaled irritants and for pharmacologic testing.105 As an induced asthma model, ragweed
pollen and Ascaris suum antigen are the most common allergens used to sensitize dogs
and to trigger the asthma phenotype. Following sensitization, dogs develop important
characteristics of human asthma such as mucus hypersecretion, cough, airway
hyperresponsiveness and airway inflammation.106-108 As in human asthma, both large and
small airways constrict in the dog asthma model.105
Unlike other animal models, the dog has been employed as a spontaneous model
of exercise-induced asthma. Dogs are active animals and they exercise naturally. Davis,
et. al., described a significant prevalence of airway inflammation after exercise in
Alaskan sled dogs raced at temperatures between 0°C and -40°C.109 In another study
involving exercise-induced asthma, Freed and collaborators used dogs to demonstrate
that exercise in a dry air environment can cause an airway constrictor response.110
Though useful as an animal asthma model, particularly for exercise-induced
asthma, the canine model also has some disadvantages. Unlike human asthma, the latephase response is not common in the canine model.108 Dermatitis is a much more
common manifestation of allergy in dogs.111
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Sheep Model
Sheep are employed as induced animal asthma models. This model provides the
ability to repeatedly measure pulmonary function with precision.112, 113 Significantly, the
methodologies and equipment used for detailed respiratory research in humans can also
be used for sheep model research.114
The respiratory systems of sheep and humans share certain commonalities. Lung
function similarities include similar physiological airflow, resistance, breathing rates,
tidal volumes, and compliance. The airway similarities include similar alveoli, airway
size, cartilage distribution, sensory nerves, capillaries, collagen and effect of histamine.
In addition, cough reflex, wheeze, bronchial glands and goblet cells are also present.67
Snibson and collaborators demonstrated that sheep repeatedly challenged with house dust
mites can reproduce a remodeling-like alteration that is very similar to the remodeling in
human lung.115
The use of the sheep model for asthma research has some limitations, including
lack of inbred and genetically manipulated sheep, lower availability of appropriate
immunologic reagents and high cost associated with purchase and husbandry.67 However,
the recent introduction of improved methods for bioengineering of transgenic animals is
sure to improve the availability and application of transgenic sheep in asthma research.
Equine Model
The horse possesses certain advantages as an animal model of asthma. Horses
spontaneously develop recurrent airway obstruction, an asthma-like disease that entails
an exacerbation remission cycle and is triggered specifically by aeroallergens including
hay and barn dust.6, 14, 66 Similarly to the human disease, horses also present clinical signs
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such as dyspnea, coughing and wheezing.3 The horse RAO model exhibits the essential
characteristics of human asthma, including airway remodeling, airway obstruction,
bronchial hyperresponsiveness, smooth muscle proliferation, airway fibrosis, Goblet cell
hyperplasia, airway inflammation and mucus hypersecretion.27, 34-37, 66, 116, 117 Airway
inflammation in RAO-affected horses is predominantly neutrophilic; however,
Polikepahad, et. al., (2008) demonstrated that, as in human asthma, some RAO-affected
horses can present a moderate eosinophilic airway infiltration.29 It is also known that
severe cases of human asthma commonly have neutrophilic inflammation as is
characteristic of horses with RAO.53, 54
Despite being considered one of the most complete animal models for asthma
research, the equine model also has some limitations. Immunological reagents are limited
for use in the horse and the horse is best suited to model asthma phenotypes that are
dominated by neutrophils.102.119 Quite significantly, the expense of keeping a horse for
research is very high. As a large animal, horses require ample space, a large amount of
food, and regular veterinary care.
Nonhuman Primate Models
Monkey models are the most suitable asthma model for investigating immune
regulation and to test new immunomodulatory therapies in asthma. The “toolbox” used
for analysis of immune response in primates is amply greater that in other models and
the genetic similarity between human and nonhuman primates may provide a very similar
course of the disease.118 Moreover, the innervation of airways in monkeys is similar to
that of human.104 Three species of nonhuman primates have been used in research:
Saimiri sciureus (squirrel monkey), Macaca mulatta (rhesus monkey), and Macaca
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fascicularis (cynomolgus monkey).119 Using house dust mites, a classic human allergen,
Schelegle, et. al., demonstrated that sensitized rhesus monkeys exhibit the critical
characteristics of human asthma. Namely, the presence of IgE-positive cells in the
tracheobronchial airway walls, airway obstruction, airway eosinophilic inflammation,
airway hyperresponsiveness, goblet cell hyperplasia, epithelial hypertrophy, and
thickening of the basement membrane zone were confirmed. Additionally, coughing,
dyspnea and decreased arterial oxygen saturation were demonstrated.120 In another study
involving infant rhesus monkeys, the incidence of smooth muscle hypertrophy and
hyperplasia were substantial in monkeys chronically sensitized to house dust mites.121
There are several limitations of using nonhuman primates as an animal model.
Most significantly, the expense of purchasing the animals, food, medical care and
housing make use of large numbers of subjects very difficult. Further, studies involving
primates are chronologically extensive68 and many ethical issues arise with the use of
captive primates.
Summary
Asthma is an economically significant human disease with high morbidity. The
spontaneous asthma-like disease of horses, termed RAO presents several improvements
over mouse models. To date these similarities have been best characterized in the stall
associated form of RAO that affects horses housed indoors in temperate regions.2,6,7 Most
significantly, RAO models the clinical hallmarks of asthma: chronic airway
inflammation, bronchial hyper-responsiveness, and reversible airway obstruction.2,5-8 The
ability of RAO to model chronic neutrophilic inflammation is noteworthy because only
the horse asthma model possesses airway neutrophilic inflammation and this
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inflammatory infiltrate correlates to the most severe asthma phenotypes.122-124 Horses
with RAO also develop increased airway smooth muscle37 which is a histologic change
of chronic airway remodeling in asthma that is not well modeled in any induced asthma
model.125-128 The purpose of this work is to investigate the histologic features of
SPARAO in order to determine if SPARAO possesses key features of remodeling that are
identified in human asthma.
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CHAPTER III
MODIFICATION OF MOVAT’S PENTACHROME I STAIN

Abstract
Movat’s pentachrome I is a stain technique with the ability to allow clear
visualization of elastic fibers, muscle, collagen, mucin, ground substance, cytoplasm and
nucleus in a single histologic section. As originally described, the stain requires process
times of 8-22 hours for consistent staining outcomes. The objective of this investigation
was to develop a modification of Movat’s pentachrome I stain that reduces the process
time and increases staining quality and consistency. The Movat’s pentachrome I stain
protocol was modified primarily by employing oven fixation of alcian blue and replacing
overnight fuchsin staining with an 8 minute crocein scarlet and fuchsin stain in acidic
conditions. Case sections from equine lung demonstrate the stain’s efficacy. This
protocol reduces prior stain times exceeding 20 hours to less than 2 hours, and provides
clear color contrast of collagen in yello, elastic fibers in black, ground substance in
indigo, muscle in red, and mucin and cartilage in bright blue. Nuclei and cytoplasm stain
dark blue and pink, respectively. This protocol’s ability to clearly differentiate multiple
histologicl features of a tissue in one stain technique, combined with the substantial
decrease in the time to complete the staining procedure, allow for increased efficiency
and accuracy during histologic evaluation of tissues.
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Introduction
Movat’s pentachrome I is a stain technique published by Movat in 1955.1 This
method provides color contrast of the tissue structures, exhibiting cytoplasm in pink,
collagen in yellow, elastic fibers in black, ground substance in purple, mucin and
cartilage in blue, nuclei in dark blue and muscle in red. In spite of its potential, this stain
is infrequently used due to lack of familiarity among pathologists, researchers, and
histology technicians, and absence of detailed and well explained protocols. In addition,
the stain is intricate, sensitive to protocol errors, time consuming (in excess of 20 hours),
can be inconsistent. Russell 2, Clifford3, Garvey4, and Schmidt5 modified Movat’s
technique but these protocols remained time consuming or have provided inconsistent
staining characteristics. Elbadawi developed a hexachrome stain technique that is very
similar to Movat pentachrome I stain.6 This technique had reduced time, but visualization
of histologic structures was still unsatisfactory.
The purpose of this work was to refine a modification of Movat’s pentachrome I
stain that is easily prepared and can be executed in under 2 hours, even by inexperienced
technicians. Lung sections are especially well suited to staining by Movat’s pentachrome
I because the lung tissue will display all the color contrasts provided by this technique.
Materials and Methods
To demonstrate this modification’s staining utility, equine lung tissue sections
collected at necropsy were used for the procedure. Tissues were fixed in 10% neutral
formalin, embedded in paraffin and sectioned at 5 µm. Sections were placed in xylene for
2 minutes followed by absolute ethanol for 2 minutes and then distilled water for 1
minute. The stock solutions utilized in this protocol include stock solutions A, B, C, and
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D, working elastic solution, and mucin stain, ammoniated ethanol, plasma stain, polyacid,
and fiber stain. The formulations of these solutions are detailed in appendix A. Sections
were placed in mucin stain for 20 minutes, washed in tap water for 3 minutes, placed in
ammoniated ethanol for 10 min at 58°C, and rinsed in running tap water for 5 minutes.
Next, sections were stained in working elastic solution for 20 minutes and rinsed in
running tap water until collagen was visualized as clear and elastin fibers were
prominent. Slides were placed in plasma stain for 12 minutes followed by 0.5% aqueous
acetic acid for 30 seconds. The slides were differentiated in polyacid until collagen
appeared clear and ground substance appeared indigo as visualized using light
microscopy. In our experience, this is a time sensitive step which may require 5-20
minutes of incubation. Slides should be examined at 5 minutes and observations repeated
at 1-3 minute intervals depending upon the intensity of blue staining remaining in the
ground substance. Slides were then rinsed in 0.5% aqueous acetic acid for 30 seconds,
placed in absolute ethanol for 2 minutes, incubated in fiber stain for 15 minutes and
rinsed using two changes of fresh absolute ethanol (1 min/rinse). Slides were placed in
xylene for 3 minutes and coverslip mounted using standard resinous mounting medium.
Results
The stain protocol was routinely completed in one hour and forty five minutes.
This modification of the Movat’s pentachrome I stain clearly differentiated cytoplasm in
pink, collagen in yellow, elastic fibers in black, ground substance in purple, mucin and
cartilage in blue, nuclei in dark blue and muscle in red (Figures 1, 2 and 3)
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Discussion
Certain features of the staining protocol were found to be particularly important to
a successful outcome. The success of the mucin stain depends directly on ammoniated
ethanol incubation. The temperature of the ammoniated ethanol must be exactly 58°C.
The working elastic solution that is used must be made fresh for the stain. If not fresh,
incomplete elastic fiber staining will occur and the elastic fibers will stain purple rather
than black. Perhaps the most significant portion of the procedure follows the staining of
elastic fibers. It is critically important to assure, with the aid of a microscope, that the
collagen has cleared of staining before proceeding.
This modification of the Movat’s pentachrome I stain improves the prior stain
protocols1-5 which require 20-22 hours to complete. This protocol consistently provides
clear differentiation of elastic fibers, muscle, collagen, mucin, ground substance,
cytoplasm and the nucleus, whereas consistency of staining is problematic in our hands
with these prior protocols. This modification of the Movat’s pentachrome I stain
technique is very useful for showing the most important tissue structures in lung,
enabling a clear comparison between normal and affected lung. This improved protocol
for Movat’s pentachrome I stain could be easily prepared and executed, even by
inexperienced histology technicians.

38

Figure 3.1

Lung, equine. Stained by Modified Movat’s pentachrome I stain, 200X.

Cytoplasm of bronchial respiratory epithelium is pink to red, nuclei are dark blue, mucus
in goblet cells is bright blue, hyaline cartilage is bright blue, smooth muscle is red,
collagen is yellow and elastin fibers are black.

Figure 3.2

Lung, equine. Stained by Modified Movat’s pentachrome I stain, 200X.

In muscular and elastic arteries, smooth muscle is red, elastic fibers in the arterial wall
and adventitia are black, collagen is yellow, and mucinous matrix in the intima and tunica
muscularis of arteries is bright blue.

Figure 3.3

Lung, equine. Bronchus in equine lung. Stained by Modified Movat’s
pentachrome I stain, 400X.

Cytoplasm of bronchial respiratory epithelium is pink to red, nuclei are dark blue, mucus
in goblet cells is bright blue, extracellular mucinous matrix is light blue, smooth muscle
fibers are red and collagen is yellow.
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CHAPTER IV
FREQUENCY OF HISTOLOGIC LESIONS OF ASTHMATIC AIRWAY
REMODELING IN HORSES WITH SUMMER PASTURE ASSOCIATED
RECURRENT AIRWAY OBSTRUCTION

Introduction
The pathogenesis of asthma has been studied in a variety of animal models
including rodents, sheep, cats, dogs, and primates1. None of these models simultaneously
demonstrate key clinical correlates to human asthma severity – namely, increased airway
smooth muscle2 and airway neutrophilia.3, 4 The induced asthma phenotype of rodents is
also a transient phenotype where, even in ‘chronic’ models, antigen sensitization cannot
be maintained, suggesting that rodent models are progressing toward a state of antigen
tolerance which is not characteristic of asthma.5-8 Larger animal models including dog,
cat, sheep, swine, horse and monkey have distinct advantages.1, 9 Facets of asthma that
are not effectively modeled in rodents, including reversible airway hyper-responsiveness
to aeroallergen challenge that is chronic and progressive, increased airway smooth
muscle, and airway neutrophilic inflammation have been demonstrated to be facets of an
equine model of asthma.10, 1112 Large animals are well suited to repeated sampling and
their physiological variables, including evaluation of pulmonary function, are more
accessible for examination and more relevant to the physiology of the human lung than
rodents.1 In addition, tissue and body fluids are easily collected and the higher quantities
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of material facilitate multiple analyses. Of the two spontaneous animal asthma models,
the horse and cat, only the horse has non-eosinophilic airway inflammation; feline asthma
is characterized by eosinophilic airway inflammation.1
Recurrent airway obstruction (RAO), also termed equine ‘heaves’, is the horse
counterpart of human asthma.12 RAO is one of the most frequent lung diseases in horses13
and is a naturally occurring allergic respiratory disorder characterized by onsets of acute
airway obstruction followed by periods of remission.14 RAO is described in two disease
variants. The variant designated as RAO or ‘heaves’ is commonly described affecting
horses in temperate areas of the world, particularly in the northern hemisphere, and is
associated with indoor housing and exposure to dust and moldy hay.12 The second form is
summer pasture-associated recurrent airway obstruction (SPARAO), which occurs in the
warm and humid summer in the southeastern United States, and United Kingdom.15
Mississippi and Louisiana are two of the 22 US states in which the prevalence of human
asthma has increased since 2009,16 a distribution that matches the region of the United
States in which horses with SPARAO manifest asthma-like signs on pasture in the
summer. Reversible airflow obstruction, bronchial hyperresponsiveness, airway
neutrophilic inflammation and mucus hypersecretion are facets of asthma that have been
well described in the stall associated form of RAO.12, 17 These facets of asthma have also
been documented in SPARAO.10, 11, 18 Similar to asthma, during RAO episodes, horses
will present with coughing and exercise intolerance, and progress to tachypnea, dyspnea
and wheezing.15 In both the indoor and pasture associated forms of RAO, clinical
remission is observed when the aeroallergens associated with the triggering environment
are removed.19
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In normal lung, terminal airways have a small contribution to airway resistance.20
In an asthmatic, lung terminal airways have a major impact on respiratory function
because their absence of cilia and lower gas velocity decrease the ability to remove
secretions that contribute to asthmatic airway obstruction.21 Histopathologic studies have
established that the asthmatic process involves both central and terminal airways22 and
measurement of the residual volume of air that is trapped during closure of terminal
airways suggests that they are responsible for the greatest gas trapping in asthma.23 Due
to ease of access, much of pulmonary research has focused on large airways while
terminal airways are less frequently investigated.24 The histologic lesions of asthma,
termed airway remodeling, correlate to advancing asthma and degrees of airflow
limitation that are not reversible.26 These lesions include airway obstruction, goblet cell
hyperplasia and metaplasia, mucus hypersecretion, thickening of airway epithelium,
smooth muscle proliferation and airway fibrosis.25-44 These lesions have also been
described in horses with RAO.38-44 Airway neutrophilic inflammation is common in adult
asthma45 and the horse presents the only spontaneous asthma model with neutrophilic
airway inflammation.1 To document similarities between this spontaneous equine model
and human asthma, the goal of this study was to objectively validate the presence and
severity of characteristic histopathologic lesions of asthma in the terminal airways of
SPARAO-affected horses.
Materials and Methods
Animals and Sample Collection
Archived lung tissue collected between 1996 and 2004 were used in this
study. Animal protocols from which these tissues were derived were approved by the
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Animal Care and Use Committee of Louisiana State University. Twenty-three horses
were included in this study. Fififteen SPARAO-affected horses included 9 American
Quarter Horses, 1 American Paint Horse, 2 Thoroughbreds, 1 Appaloosa, and 2 mixed
breed horses. The SPARAO horses, 9 females and 6 geldings, ranged from 10 to 27 years
of age (mean (x) + standard deviation (SD), 15.4 + 5.3 years). Eight clinically normal
horses included 3 American Quarter Horses, 1 American Saddlebred, 3 Thoroughbreds,
and 1 Appaloosa/Thoroughbred cross. Control horses, 3 females and 5 geldings, ranged
from 7 to 22 years of age (x=15.6 + 5.3 years). The diagnosis of SPARAO was based on
the history of recurrent obstructive respiratory disease following exposure to summer
pasture in the southeastern United States. This was substantiated by the following
findings during summer that abated during cooler seasons: pronounced expiratory
wheezes throughout the lung fields; tracheal rattle, cough, nostril flaring and prominent
abdominal lift; increased clinical scores of respiratory effort (CSRE); and the presence of
airway inflammation as documented by cytologic analysis of bronchoalveolar lavage
fluid (BALF).10 The clinical score of respiratory effort, is based upon subjective scoring
of nostril flare and abdominal lift on a scale of 1-4 and scores > 4.5 substantiate dyspnea
in horses with SPARAO.10
Twelve affected horses were euthanized during clinical exacerbation, eleven had
wheezes upon auscultation of the lungs during tidal breathing. Their assigned CRSE
ranged from 4.5 to 7.5 (x = 5.4 + 0.8), and cytologic evaluation of BALF confirmed a
predominance of non-degenerate neutrophils, ranging from 10 to 90%, (x = 60 + 26 %),
and ΔPplmax (maximal change in pleural pressure during respiration) ranging from 12 to
58 mm H2O (x = 29 + 13). Three affected horses were euthanized during clinical
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remission. None of these three horses had abnormal lung sounds upon auscultation of the
lungs with a re-breathing bag. During remission, SPARAO horses had assigned CRSE of
3 (x = 3 + 0), and cytologic evaluation of BALF revealed neutrophils ranging from 1 to
3% ( x = 1.7 + 1.2 %), and ΔPplmax ranging from 1 to 7 mm H2O (x = 4.7 + 3.2). All
non-affected horses had normal bronchovesicular sounds upon auscultation of the lungs
with a re-breathing bag, assigned CSRE ranging from 2.0 to 3.0 (x = 2.3 + 0.5), and
between 1% to 10% neutrophils (x = 6 + 4 %) evident via cytologic evaluation of BALF.
All horses were euthanized by intravenous administration of sodium pentobarbital
(100 mg/kg, IV) at least 24 hours after BALF sample collection. Gross postmortem
evaluation of the lungs was performed and the lungs were removed from the thoracic
cavity. Of the twelve affected horses euthanized during clinical exacerbation, eleven had
overinflation of the lungs evidenced by failure to collapse when the thoracic cavity was
opened. The lungs of all of the SPARAO-affected horses euthanized during remission
and all non-affected horses collapsed when the thoracic cavity was opened and none
appeared overinflated. Two specimens measuring 3x3x3 cm were collected from the right
apical, left apical, right diaphragmatic, left diaphragmatic and accessory lung lobes,
respectively. Each specimen was selected to contain at least 1 bronchus with diameter
between 4 to 8 mm. Immediately after collection, specimens were immersed in aqueous
buffered zinc formalin for 24 hours prior to routine processing, embedding in paraffin,
and sectioning.
Tissue preparation and histological Staining Techniques
Histologic sections were cut at 5μm and stained with hematoxylin-eosin stain or a
modification of Movat’s Pentachrome I Stain as described in Chapter 3. Movat’s
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pentachrome I stain provides color contrast that enables visualization of elastic fibers,
muscle, collagen, mucin, ground substance, cytoplasm and nucleus in a single histologic
section. Cytoplasm is readily evident by its conventional pink staining, collagen stains
yellow, elastic fibers black, ground substance indigo, the nucleus dark blue, muscle red,
and mucin and cartilage bright blue.
All non-cartilaginous airways were identified on each slide and labeled. Fifteen
non-cartilaginous airways were randomized and evaluated for histologic evidence of
asthmatic airway remodeling including increases in airway smooth muscle,
peribronchiolar fibrosis with collagen, peribronchiolar elastin fibers, airway occlusion by
mucus or inflammatory cells, airway adventitial inflammation, and goblet cell
hyperplasia and metaplasia. Initial review of lung sections from horses with SPARAO
revealed a complex cellular disorganization at the level of the terminal bronchus. This
lesion, which we have named terminal bronchiolar remodeling, is characterized by
varying degrees of extension of smooth muscle, collagen and elastic fibers into
surrounding alveolar ducts, alveoli and alveolar septal walls together with varying
degrees of terminal bronchiolar epithelial hyperplasia. These seven histologic parameters
were evaluated and scored in each airway as 0 (normal), 1 (mild), 2 (moderate) and 3
(severe) according to criteria listed in Table 1
Statistics
A mixed effects logistic regression model was used to describe the effect of
independent variables on the probability of reporting the histologic outcome using PROC
GLIMMIX (SAS 9.1 for Windows, SAS Institute, Inc., Cary, NC). Histological
parameter scores were dichotomized with scores of 0 considered negative (0), and scores
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of 1, 2 or 3 considered positive. The independent variables in the model were disease
status (SPARAO vs control), lung lobe, and age where horses were grouped as ≤15 years
and >15 years. The hierarchical structure of the data was accounted for by including lung
lobe (horse ID) and horse ID as random effects. Pairwise comparisons of lobe effects
were determined using least squares means. The threshold for statistical significance was
p<0.05.
Results
Table 2 summarizes the comparisons of the 7 histologic parameters by disease
status and age. The frequency of all seven histologic parameters was significantly
increased in horses with SPARAO relative to control horses. Increases in airway smooth
muscle (OR=2.5, p<0.001), terminal bronchiolar remodeling (OR=3.7, p<0.0001), goblet
cell hyperplasia/metaplasia (OR=37.6, p<0.0001), and peribronchiolar elastin fibers
(OR=4.2, p<0.001) were highly significant in SPARAO horses. Increases in
peribronchial fibrosis (OR=3.8, p=0.01), airway occlusion by mucus and inflammation
(OR=4.2, p=0.04,) and airway adventitial inflammation (OR=3.0, p=0.01) also met the
criteria established for statistical significance.
The frequency of histologic lesions was not significantly different between age
groups for increased airway smooth muscle (OR=1.5, 0.9-2.6; p=0.11), airway occlusion
by mucus and inflammation (OR=2.5, 0.7-9.3; p=0.17), airway adventitial inflammation
(OR=1.3, 0.5-3.0; p=0.57), and goblet cell hyperplasia/metaplasia (OR=0.6, 0.4-1.0;
p=0.6). Relative to younger horses, older horses had significantly greater peribronchial
fibrosis (OR=2.7; p=0.04), terminal bronchial remodeling (OR=2.4; p=0.0004), and
peribronchiolar elastin fibers (OR=2.9; p=0.004).
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Significant differences in the frequency of increased airway smooth muscle
(p=0.001), terminal bronchiolar remodeling (p=0.0001), and peribronchiolar elastin fibers
(p<0.0001) were evident between lung lobes. In all pairwise comparisons between the
accessory, left apical and right apical lung lobes, the frequencies of increased airway
smooth muscle (p>0.70), terminal bronchiolar remodeling (p>0.6), and peribronchiolar
elastin fibers (p>0.08) did not differ significantly between lung lobes. However, all
pairwise comparisons of the left or right diaphragmatic lobe to either the accessory, left
apical or right apical lung lobes identified statistically significant increases in airway
smooth muscle (p<0.01) and terminal bronchiolar remodeling (p<0.05). The frequency of
increased airway smooth muscle was slightly higher in the right diaphragmatic lobe than
the left diaphragmatic lobe, but was not significant (p=0.44). Frequency of terminal
bronchiolar remodeling was significantly higher in the right diaphragmatic lobe than the
left diaphragmatic lobe (p=0.02). In the case of peribronchiolar elastin fibers, pairwise
comparisons of the left or right diaphragmatic lobe to either the left apical or right apical
lung lobes identified a significant increase in peribronchiolar elastin fibers (p<0.017) in
the left and right diaphragmatic lung lobes. The frequency of increased peribronchiolar
elastin fibers was slightly higher in the left diaphragmatic lobe than the right
diaphragmatic lobe but this difference was not statistically significant (p=0.09). The
frequency of peribronchiolar elastin fibers in the accessory lobe was not significantly
different from the right diaphragmatic lung lobe (p=0.10). The accessory lobe had fewer
peribronchiolar elastin fibers than the left diaphragmatic lobe and this difference was
highly significant (p<0.0001).
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Discussion
Asthma is a clinical syndrome characterized by variable bronchial hyperresponsiveness leading to respiratory distress and airway obstruction. Small airways are
now recognized to have a major impact on respiratory function in asthma. Measurements
of the residual volume of air that is trapped during closure of terminal airways suggests
that they are responsible for the greatest gas trapping in asthma.23 This has been
attributed to the absence of cilia and have lower gas velocities in small airways that
impair removal of respiratory secretions.22 Impaired removal of respiratory secretions
from small airways and the resulting obstruction of these airways is a major contributor
to impaired gas exchange in asthma because small airways link regions of pulmonary gas
exchange to the larger conducting airways.
Despite physiologic evidence for the importance of small airways in asthma, and
histopathologic evidence that the asthmatic process involves both central and terminal
airways,22 small airway pathology in asthma has not been as extensively investigated as
the pathology of larger airways. This reflects the relative ease of accessing the larger
airways for bronchoscopic biopsy. In this investigation the characteristic histologic
components of asthma pathology, collectively termed ‘remodeling’ were evaluated in
smaller cartilaginous and non-noncartilagenous airways from horses with SPARAO, a
proposed equine model of non-eosinophilic asthma. These lesions include smooth muscle
hypertrophy or hyperplasia, peribronchiolar fibrosis with collagen deposition, airway
occlusion by mucus or inflammatory cells, airway adventitial inflammation, and goblet
cell hyperplasia or metaplasia. It is generally accepted that airway remodeling is closely
related to the progression and severity of asthma.29 This investigation also identified
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complex cellular disorganization at the level of the terminal bronchus characterized by
varying degrees of extension of smooth muscle, collagen and elastic fibers into
surrounding alveolar ducts, alveoli and alveolar septal walls and accompanied by varying
degrees of terminal bronchiolar epithelial hyperplasia. To our knowledge, this is first
description of this lesion which has been termed terminal bronchiolar remodeling.
Finally, the presence of increased elastic fibers in the airway, a histologic finding that is
increased in severe fatal asthma, was also characterized.45 The use of a modified
pentachrome stain in our research was extremely important for providing a detailed view
of the most important microscopic changes in lungs. The stain modification developed in
the course of this research significantly shortened the duration of the staining protocol
and enabled the evaluation of multiple tissue components within a single stained section,
making it of great value for histopathologic lung research.
Increases in airway smooth muscle have been previously identified in SPARAO.42
In our study, an increase in smooth muscle in the small airways constituted a highly
significant difference between SPARAO horses and controls. Horses with SPARAO were
2.5 times more likely to have increased airway smooth muscle than control horses. Our
statistical model included disease, age and lung lobe as independent variables, such that
this odds ratio is not biased by age. Further, the frequency of increased airway smooth
muscle was not statistically significantly different between age groups. Similar to our
results, Herszberg and colleagues41 demonstrated that smooth muscle proliferation is
much more accentuated in small airways than in large airways in horses with barn
associated RAO. In association with staining that documented proliferation of smooth
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muscle cells, these authors concluded that airway smooth muscle hyperplasia is an
important factor in airway obstruction and hyper-responsiveness in barn associated RAO.
In human asthmatics, investigations of airway smooth muscle are primarily
derived from large airways which are accessible using endoscopic biopsy techniques.
Proliferation of airway smooth muscle in large airways is greater in subjects with severe
asthma, as compared with the less severe forms of the disease,46, 47 indicating that airway
smooth muscle hyperplasia is the key structural change in the progression from less
severe to more severe forms of human asthma. Mauad and colleagues recently reported
increased airway smooth muscle in small airways of fatal asthma in young patients (mean
age 32 years), further supporting a role for increased airway smooth muscle as a marker
of advancing asthma severity.48 In this investigation of small airways from a spontaneous
equine model of asthma, smooth muscle could be identified in some instances to extend
into the terminal bronchioles. Though cells were not stained to specifically identify
proliferation in this investigation, the presence of muscle in terminal bronchiolar airways,
which are normally devoid of smooth muscle, confirms the presence of cellular
hyperplasia or metaplasia/transdifferentiation and not airway smooth muscle
hypertrophy. This lesion would be anticipated to limit alveolar ventilation and, to our
knowledge, has not been described in human asthmatics. Additional investigations of
smooth muscle in small airways are necessary to substantiate the importance of structural
changes in airway smooth muscle of small airways as a factor that can differentiate
severe asthma from the less severe types. However, it is important to recognize that
asthma is a multifaceted disease with heterogeneous phenotypes. Therefore, more than
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one histopathologic lesion could conceivably be correlated to asthma severity in different
subtypes of the disease.
Collagen deposition in the airways is a component of airway remodeling in
asthma.28 Airway fibrosis plays a role in the pathophysiology of incompletely reversible
airway obstruction that occurs in some asthmatics.28 Subepithelial fibrosis has been
associated with asthma severity, frequency, duration of symptoms, and the degree of
airway hyper-reactivity29,49-51. However, the magnitude of collagen proliferation found in
large airways does not differentiate severe asthma from milder forms of this condition.46,
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Furness and colleagues have investigated pulmonary lesions associated with the barn-

associated form of RAO and have suggested that collagen deposition may not be a feature
of RAO. Their results demonstrated that noncartilaginous airways of affected horses did
not present differences in the amount of collagen compared with airways from clinically
normal horses.53 Our study, by contrast, demonstrates that, relative to non-diseased
control horses, horses with SPARAO have a significantly greater frequency of
peribronchiolar fibrosis. This finding is in line with that of airway remodeling that is
described in association with chronic asthma and may have been facilitated by the
utilization of pentachrome staining that clearly stains collagen yellow.
Airway occlusion by mucus and/or inflammatory cells occurs commonly in horses
with barn-associated RAO, where a strong correlation between disease exacerbation and
mucus hypersecretion has been identified in SPARAO.43 Occlusion occurs even during
remission when inflammation, clinical signs and bronchospasm are reduced or
nonexistent.54 In this investigation the odds of a horse with SPARAO having airway
occlusion by mucus and/or inflammatory cells was 4.2 times greater than a horse without
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SPARAO. This finding is consistent with that of Costa whose investigation identified
mucus accumulation in small airways as a predominant histopathologic alteration in the
lungs of SPARAO-affected horses.11 Similar to that study, our quantitative approach
clearly demonstrates that airway occlusion by mucus and/or inflammatory cells is
significantly increased in horses with SPARAO. Horses with SPARAO were 4.2 times
more likely to have airway occlusion by mucus and inflammatory cells than were nondiseased control horses. Frequency of airway occlusion by mucus and/or inflammatory
cells was not significantly different in horses under 15 years and over 15 years of age,
with an odds ratio of 2.5 and confidence interval that included unity, indicating that age
was not a factor in the frequency of this lesion. Accordingly, airway occlusion by mucus
and inflammation is conceivably a major contributor to clinical signs during disease
exacerbation. In human asthma, mucus plugs combined with an admixture of
inflammatory cells have been reported in cases of sudden asthma death.55 Also, earlier
investigations have demonstrated a 31 fold increase in mucus accumulation in terminal
airways of patients who died of severe acute asthma attack.25 Our finding of significant
airway obstruction by mucus and inflammatory cells in SPARAO is consistent with the
previously indicated relevance of airway occlusion in inducing the clinical signs observed
in severe asthma.
Goblet cell hyperplasia/metaplasia is acknowledged as a key component of airway
remodeling in asthma.26,29,45,46 During our study we recognized some confusion in the
literature with regards to the use of the term metaplasia and hyperplasia. Not
infrequently, metaplasia has been referred to as hyperplasia. Hyperplasia refers to
proliferation that yields the same parental cell type, while metaplasia refers to cellular
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differentiation to an alternate cell type. By contrasting the distribution of goblet cells in
horses with RAO and normal horses using morphometric investigation, Range et al.
determined that metaplasia predominates in the bronchioles of horses with barnassociated RAO, whereas goblet cell hyperplasia is evident in bronchi.56 Goblet cell
hyperplasia/metaplasia contributes to airway obstruction via increased cell size and
increased production of mucus. In this investigation, goblet cell hyperplasia/metaplasia
constituted a highly significant difference between SPARAO horses and controls. Horses
with SPARAO were 37.6 times more likely to have goblet cell hyperplasia/metaplasia
than were control horses. Frequency of goblet cell hyperplasia and metaplasia was not
significantly different between age groups with an odds ratio of 0.63 and confidence
interval that included unity, indicating that age was not a factor in the frequency of this
lesion. Therefore, goblet cell hyperplasia/metaplasia is a lesion whose increasing
frequency is highly significantly associated with SPARAO. In fact, the frequency of
goblet cell hyperplasia/metaplasia tended to decrease with age making this lesion helpful
in differentiating the histopathologic diagnosis of SPARAO from other causes of
respiratory impairment, particularly in horses over 15 years of age.
Analyses of BALF collected from SPARAO-affected horses have demonstrated
that the inflammatory exudate consists primarily of neutrophils and lymphocytes and the
presence of eosinophils is less common.11 In addition, cough frequency has been strongly
correlated to the magnitude of neutrophil counts in BALF of barn-associated RAOaffected horses.43 This investigation demonstrated that airway adventitial inflammation,
which was predominantly neutrophilic in nature, is a histopathologic feature that is
significantly increased in horses with SPARAO. Horses with SPARAO were 3.0 times
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more likely to have airway adventitial inflammation than were non-diseased control
horses. The frequency of airway adventitial inflammation was not significantly different
in horses under 15 years and over 15 years of age, with an odds ratio of 1.27 and
confidence interval that included unity, indicating that age was not a factor in the
frequency of this lesion. Our findings are very similar to previous research involving
severe human asthma that is also characterized by neutrophilic lung inflammation. In
fatal asthma attacks, bronchiolar neutrophilic inflammation predominates and
eosinophilic inflammation is less prevalent. This finding has led to the hypothesis that
fatal attacks of asthma may be triggered by stimuli that elicit neutrophilic inflammatory
responses.57 Neutrophils have also been recognized as the major inflammatory cell
present in acute severe asthma that necessitates mechanical ventilation.58 Small airway
inflammation is highly correlated with severe asthma attacks. Previous research has
demonstrated that, in severe cases of asthma, the most accentuated inflammatory process
occurs in the noncartilaginous airways, contributing to the predisposition of small
airways to be the major location of obstruction.35, 59 The common finding of neutrophilic
small airway inflammation observed in SPARAO, barn-associated RAO, and in human
severe asthma, suggest that these spontaneous equine diseases may be useful to
investigate facets of neutrophilic inflammation in severe human asthma.
In the review of several hundred sections for this work, abnormalities of the
terminal bronchioles characterized by varying degrees of extension of smooth muscle,
collagen and elastic fibers into surrounding alveolar ducts, alveoli and alveolar septal
walls and accompanied by varying degrees of terminal bronchiolar epithelial hyperplasia
were evident. This combination of changes at the level of the terminal bronchiole has to
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our knowledge not been previously described in the literature. We postulate, based upon
the associated compromise of the terminal bronchiole which is the gateway to the
alveolus, that terminal bronchiolar remodeling impairs alveolar ventilation in a fashion
that is proportional to the severity of the lesion. Relative to non-diseased control horses,
horses with SPARAO have a greater frequency of terminal bronchiolar remodeling that is
highly significant. Horses with SPARAO were 3.7 times more likely to have terminal
bronchiolar remodeling in their small airways than control horses. Age was also a highly
significant factor that impacted the frequency of terminal bronchiolar remodeling in a
manner that was independent of disease status. Horses greater than 15 years of age were
2.4 times more likely to have terminal bronchiolar remodeling than horses less than 15
years of age. This data indicates that terminal bronchiolar remodeling is a feature of the
summer pasture associated form of RAO. However, frequency of this lesion was also
increased in horses over 15 years of age, independent of disease status. Accordingly,
from a clinical standpoint, the presence of terminal bronchiolar remodeling in horses over
15 years of age does not exclusively implicate SPARAO as a disease process.
The finding of increased elastin fibers in the peribronchiolar region of horses with
SPARAO is novel. This lesion has also not been previously reported in barn-associated
RAO. This observation was fortuitous because of the use of pentachrome staining that
clearly stains elastin fibers. Peribronchiolar elastin fiber frequency was increased in
horses with SPARAO and this increase was highly significant in relation to normal
control horses. Horses with SPARAO were 4.2 times more likely to have increased
peribronchiolar elastin fibers in their small airways than were control horses. Age was
also a highly significant factor that strongly positively impacted the frequency of
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peribronchiolar elastin fibers in a manner that was independent of disease status. Horses
greater than 15 years of age were 2.9 times more likely to have peribronchiolar elastin
fibers than horses less than 15 years of age. This data indicates that peribronchiolar
elastin fibers are a feature of the summer pasture associated form of RAO. However, the
frequency of the lesion in horses over 15 years of age makes it difficult to exclusively
implicate SPARAO as the etiology when increased elastin fibers are detected in the small
airways of horses over 15 years of age. However, in such cases clinical characteristics of
the disease would also be collectively interpreted to clarify the relevance of SPARAO as
a diagnosis.
In conclusion, goblet cell hyperplasia/metaplasia and increased smooth muscle
with evidence of hyperplasia are two lesions whose frequency is increased in a highly
significant manner in horses with SPRAO and for which there is no significant increase
in lesion frequency in horses over 15 years of age. Airway adventitial inflammation and
airway occlusion by mucus and inflammation demonstrate a statistically significant
increase in frequency and there is also no significant increase in frequency of these
lesions with increasing age. These 4 lesions: goblet cell hyperplasia/metaplasia, increased
airway smooth muscle, airway adventitial inflammation and airway occlusion by mucus
and inflammatory cells, provide a panel of histopathologic findings whose collective
presence is are useful in refining the histopathologic diagnosis of SPARAO.
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Table 4.1

Criteria for histologic scoring of lung from horses with summer pasture associated recurrent airway obstruction
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Table 4.2

Statistical analysis of the frequency of 7 histologic lesions based upon
disease status and age

Histological Parameter

Fixed Effects

Odds Ratio

P-Value

Smooth muscle hypertrophy and hyperplasia

Status

2.515

0.0009

Age Group

1.536

0.0014

Status

3.750

0.0107

Age Group

2.724

0.0437

Status

4.179

0.0369

Age Group

2.504

0.1690

Status

3.008

0.0127

Age Group

1.274

0.5739

Status

3.686

<.0001

Age Group

2.394

0.0004

Status

37.622

<.0001

Age Group

0.628

0.0629

Status

4.237

0.0002

Age Group

2.881

0.0043

Peribronchiolar fibrosis with collagen

Airway occlusion by mucus or inflammatory
cells

Airway adventitial inflammation

Terminal Bronchiolar Remodeling

Goblet Cells Hyperplasia or Metaplasia

Peribronchiolar Elastin Fibers
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APPENDIX A
CHEMICAL SOLUTIONS USED IN THE MODIFIED MOVAT’S
PENTACHROME I STAIN
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Chemical Solutions Used in the Modified Movat’s Pentachrome I Stain


Stock solution A

Orcein - 0.5 g,
Hydrochloric acid, concentrated - 0.5 ml
Ethanol, 70% - 250 ml


Stock Solution B

Hematoxylin - 4 g
Ethanol, 100% - 80 ml


Stock Solution C

Ferric Chloride – 4.8 g
Distilled water – 45 ml


Stock Solution D

Iodine – 0.5 g
Potassium Iodine – 1g
Distilled water – 48 ml


Working Elastic Solution

Stock Solution A – 75 ml
Stock Solution B – 24 ml
Stock Solution C – 15 ml
Stock Solution D – 15 ml


Mucin Stain

Alcian Blue – 1 g
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Acetic Acid, Glacial – 1 ml
Distilled water – 99 ml


Ammoniated Ethanol

Strong ammonia – 5 ml
Ethanol, 95% – 95 ml


Plasma stain

Crocein scarlet 1% aqueous – 4 ml
Acid fuchsin 1% aqueous – 1 ml
Acetic acid, 0.5% - 95 ml


Polyacid

Phosphotungstic acid – 5 g
Distilled water – 100 ml


Fiber Stain

Spanish saffron – 3g
Ethanol, 100% - 48 ml
Close the container tightly and keep this suspension in a 60°C oven for two days. Then
pour the liquid out and store it in a dark sealed container to prevent hydration.
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